AstraZeneca Results Presentation Deck

Emerging Markets - H1 2023 Total Revenue +9% at CER to $6.3bn, +22% at CER ex-COVID-19 medicines Total Revenue ($m) 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 Q2 Q3 2021 Q4 China Emerging Markets ex-China COVID-19 medicines Q1 37 Growth at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. CER = constant exchange rates; EM = Emerging Markets. Q2 2022 Q3 Q4 Q1 APPENDIX | Emerging Markets 2023 Q2 B

View entire presentation